CN112159845B - Application of circular RNA as pancreatic cancer diagnosis marker - Google Patents
Application of circular RNA as pancreatic cancer diagnosis marker Download PDFInfo
- Publication number
- CN112159845B CN112159845B CN202010908496.8A CN202010908496A CN112159845B CN 112159845 B CN112159845 B CN 112159845B CN 202010908496 A CN202010908496 A CN 202010908496A CN 112159845 B CN112159845 B CN 112159845B
- Authority
- CN
- China
- Prior art keywords
- pancreatic cancer
- circ
- hsa
- circular rna
- rna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
The invention discloses an application of a circular RNA as a pancreatic cancer diagnosis marker, wherein the circular RNA is RNA hsa _ circ _0047834, the nucleotide sequence of the circular RNA is shown as SEQ ID NO.1, the sequence forms a closed circular RNA molecule through reverse splicing, the circular RNA is characterized in that the circular RNA hsa _ circ _0047834 and the application of gene related products thereof in pancreatic cancer diagnosis, and a kit for detecting the relative expression of hsa _ circ _0047834 comprises an upstream primer GTTTTCACTGTTCGACCGGC; the downstream primer GCTGCATCCCAATCGCAAAT has the advantages of providing a pancreatic cancer detection method which is simple to operate, high in sensitivity, strong in specificity, short in period and stable in result by detecting the relative expression of hsa _ circ _0047834 in pancreatic cancer tissues and plasma.
Description
Technical Field
The invention belongs to the field of molecular biology, and particularly relates to application of circular RNA hsa _ circ _0047834 as a pancreatic cancer diagnosis marker.
Background
Pancreatic cancer is a malignant tumor of the digestive system, has hidden onset, rapid development, difficult early diagnosis and poor prognosis. The worldwide morbidity and mortality of pancreatic cancer is rising year by year, and is at the 7 th mortality of Chinese malignancies. Surgical resection is currently still the primary treatment for pancreatic cancer, however, the 5-year survival rate for surgical patients is still as low as 6%. The key for improving the pancreatic cancer prognosis mainly lies in early diagnosis and early treatment, and early and timely intervention is carried out by detecting related molecular markers of high-risk patients. CA19-9 has been used clinically for many years, but its sensitivity, specificity are relatively low, can't meet the clinical needs. Circulating Tumor Cells (CTCs) are a novel minimally invasive technique for tumor diagnosis, monitoring and therapy. However, given the heterogeneity of cells, DNA, molecular marker types, molecular targets and exosomes, etc., of different types of pancreatic tumors, and the extremely low levels of CTCs in blood, there are still considerable difficulties with diagnosis of pancreatic cancer.
Circular RNAs are a class of non-coding RNAs with a continuous covalently closed circular structure that has been found to be species-conservative and tissue-specific. With the continuous development of next generation sequencing technologies, especially the emergence of RNA sequencing technologies, more and more studies have confirmed that circular RNA is widely expressed in cytoplasm. In addition, they have received attention due to their specificity in expression, complexity in regulation, and important roles in the pathogenesis of many diseases, particularly cancer. Unlike linear RNA, circular RNA has neither 5'-3' polarity nor a poly A tail. Is not affected by exonucleases, and is stable and widely existed in biology. Without free 3 'and 5' ends, these molecules are not readily degraded by nucleases, making them ideal biomarkers for early diagnosis of pancreatic cancer.
The real-time fluorescent quantitative PCR is a method of adding a specific probe or fluorescent dye marked by fluorescence into a PCR reaction system, monitoring the whole PCR process in real time by using a fluorescent signal, and finally carrying out quantitative analysis on a target gene through a standard curve. Compared with the traditional PCR detection method, the method has the advantages that the sensitivity and the specificity are obviously improved. Therefore, quantitative detection of the change of the circular RNA in the tissues and blood plasma of the pancreatic cancer tumor patient has important significance for the research of early diagnosis, generation mechanism, curative effect evaluation and the like of pancreatic cancer, and the method is more suitable for scientific research units and hospital operation.
The circular RNA hsa _ circ _0047834 is derived from PMAIP1 gene, is a Bcl-2 homeodomain-only protein, can induce expression of p53 gene and affect DNA damage. In addition, it has been shown by studies that PMAIP1 plays an important regulatory role in the development of colorectal, breast and endometrial cancers. At present, no research report related to a detection kit for detecting hsa _ circ _0047834 by using real-time fluorescent quantitative PCR in pancreatic cancer is published at home and abroad.
Disclosure of Invention
The invention aims to provide application of a circular RNA which has high sensitivity and specificity and is positively correlated with the prevalence rate of pancreatic cancer as a pancreatic cancer diagnosis marker and a detection kit thereof.
The technical scheme adopted by the invention for solving the technical problems is as follows: a circular RNA is RNA hsa _ circ _0047834, the nucleotide sequence of the circular RNA is shown in SEQ ID NO.1, the sequence forms a closed circular RNA molecule through reverse splicing, and the circular RNA hsa _ circ _0047834 and the related products of the gene thereof are applied to pancreatic cancer diagnosis.
The circular RNA hsa _ circ _0047834 is used as a pancreatic cancer diagnostic reagent.
The application of the circular RNA hsa _ circ _0047834 in preparing pancreatic cancer molecule targeted drugs.
And the application of the circular RNA hsa _ circ _0047834 gene segment or gene splicing body in preparing pancreatic cancer molecule targeted drugs.
And the protein or polypeptide fragment coded by the circular RNA hsa _ circ _0047834 gene is applied to the preparation of pancreatic cancer molecule targeted drugs.
And the protein antibody coded by the circular RNA hsa _ circ _0047834 gene is applied to the preparation of pancreatic cancer molecule targeted drugs.
A kit for detecting the relative expression of the hsa _ circ _0047834 gene of circular RNA related to pancreatic cancer comprises a pair of specific amplification primers of the hsa _ circ _004783 gene, and the specific nucleotide sequences are as follows: an upstream primer: 5'-GTTTTCACTGTTCGACCGGC-3', respectively; a downstream primer: 5'-GCTGCATCCCAATCGCAAAT-3' are provided.
The kit also comprises a fluorescent quantitative PCR reaction system, which comprises the following components: 10 μ l SYBR, 0.4. mu.l ROX, 1 μ l cDNA template, 0.5 μ l upstream primer at a concentration of 52.6 μ g/mL, 0.5 μ l downstream primer at a concentration of 48.2 μ g/mL, ddH2O was supplemented to 20 μ l, and the conditions for the quantitative PCR were as follows: 95 ℃ for 5 min; circulating for 35 times at 95 ℃ for 15s, 59 ℃ for 30s and 72 ℃ for 30 s; 95 ℃ for 1 min, 55 ℃ for 30s, 95 ℃ for 30 s.
Compared with the prior art, the invention has the advantages that: the invention discloses a kit for detecting circular RNA hsa _ circ _0047834 related to pancreatic cancer and application thereof in preparing a pancreatic cancer detection reagent or a pancreatic cancer auxiliary diagnosis reagent, wherein the hsa _ circ _0047834 quantitative detection kit comprises a pair of specific amplification primers for detecting hsa _ circ _0047834 and a pair of specific primers for internal reference beta-actin, the expression of hsa _ circ _0047834 and beta-actin in a subject tissue is detected through SYBR Green fluorescent quantitative PCR, the expression of hsa _ circ _0047834 in a pancreatic cancer patient sample and a normal sample is compared through calculation, and the relative expression parameter of hsa _ circ _0047834 is calculated to be used for auxiliary diagnosis of pancreatic cancer. Compared with the traditional pancreatic cancer detection technology, the method has the characteristics of simple operation, high sensitivity, strong specificity, short period and the like, and is beneficial to early diagnosis and treatment of pancreatic cancer.
Drawings
FIG. 1 is a melting curve of hsa _ circ _0047834 fluorescent quantitative PCR;
FIG. 2 is a graph of the expression level of hsa _ circ _0047834 in pancreatic cancer samples. A. Expression level of hsa _ circ _0047834 in pancreatic cancer tissue and paired normal tissue (n = 20); B. (ii) the expression level of hsa _ circ _0047834 in plasma samples of pancreatic cancer patients and healthy controls (n = 21);
FIG. 3 is a ROC curve of serum hsa _ circ _0047834 for differentiating pancreatic cancer patients from healthy subjects, with an area under the curve of 0.8027.
Detailed Description
The invention is described in further detail below with reference to the following examples of the drawings.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
1. 20 cases of pancreatic cancer tissues surgically excised in the eastern academy hospital of Lihuili Hospital, Ningbo City, 6.2018 to 2020 and corresponding paired para-carcinoma tissues were collected. At the same time, 30 total plasma samples were collected from pancreatic cancer patients, and 30 healthy human plasma samples were collected.
Inclusion criteria were: 1. all blood specimen collection work needs informed consent of patients and family members; 2. the pancreatic duct adenocarcinoma patient needs pathological confirmation after operation or puncture cytology biopsy with cancer cells under ultrasonic guidance; 3. diagnosis of chronic pancreatitis refers to the consensus of the american society of pancreas diseases (APA) in 2014.
Exclusion criteria: 1. patients who undergo chemotherapy or radiotherapy with the new assistance before the pancreatic ductal adenocarcinoma operation; 2. patients with benign or borderline malignant tumors of the pancreas; 3. patients with pancreatic metastatic cancer (renal cancer, lung cancer, etc. metastasize to the pancreas); 4. patients with serous cystadenocarcinoma or mucinous cystadenocarcinoma; 5. acute pancreatitis manifestations appear in three months in patients with chronic pancreatitis; 6. the patients with chronic pancreatitis have a tendency to become malignant within half a year of follow-up visit; 7. grade 5 or above grade 5 hemolysis occurs in blood samples from patients.
2. Tissue RNA extraction
(1) Weighing about 50 mg of pancreatic cancer tissue or a tissue sample beside the cancer, adding 1 ml of TRIzol solution, sufficiently shearing the tissue, then stirring the tissue into pulp by using a tissue homogenizer, and standing for 5min on ice;
(2) adding 200 μ l of chloroform into an EP tube, shaking with vortex to mix thoroughly, standing on ice for 5min, centrifuging at 4 deg.C and 12000 g for 15 min;
(3) centrifuging, adding the supernatant of the sucked sample into a new EP tube, adding 500 mul of isopropanol, performing vortex oscillation to fully mix the mixture, standing the mixture for 10min on ice, and centrifuging the mixture for 15 min at 4 ℃ and 12000 g;
(4) after centrifugation, the supernatant in the EP tube is gently discarded, 1 ml of 75% ethanol prepared by enzyme-free water is added to wash the RNA precipitate, the RNA precipitate is centrifuged for 5min at the temperature of 4 ℃ and 8000 g, and the washing operation is repeated for 1 time;
(5) carefully pouring out the supernatant in the EP tube, allowing the EP tube to naturally air dry, then adding a proper amount of enzyme-free water according to the size of the RNA precipitate, and gently blowing and beating to fully dissolve the RNA.
3. Plasma RNA extraction
(1) Collecting 5mL of whole blood, placing the whole blood in an EDTA anticoagulation collecting tube, slightly inverting the whole blood for several times, placing the whole blood at 4 ℃, centrifuging the whole blood at 1500 g for 5min, taking out the collecting tube, sucking the supernatant, and transferring the supernatant to a 1.5mL nuclease-free tube (taking care not to puncture the cells in the lower layer); centrifuging again at 1500 g for 10min, sucking the supernatant into a new nuclease-free tube, and storing in a refrigerator or liquid nitrogen tank at-80 deg.C;
(2) the plasma samples were removed from a-80 ℃ freezer, slowly dissolved on ice to a liquid state, 250 μ l of plasma was taken to a new 1.5ml EP tube, 750ul Trizol LS was added, placed in a vortexer and vortexed vigorously for 20min, and allowed to stand at room temperature for 5min, with the subsequent steps consistent with the tissue RNA extraction steps.
4. RNA purity analysis
The purity of the RNA is detected by using an ultraviolet visible spectrophotometer, the purity of the RNA is judged by comparing the A260/A280, the ratio is within the range of 1.8-2.0, the purity of the RNA is considered to be good, and the method is suitable for subsequent experiments.
5. Reverse transcription reaction
After adding the above reagent to 200. mu.l of a nuclease-free EP tube, the mixture was gently mixed by a pipette, and the mixture was immediately placed on ice after being subjected to a water bath at 37 ℃ for 5 minutes. Adding 4 mu l of 5 XTRT Master Mix, gently mixing by using a pipette, and placing the mixture in a PCR (polymerase chain reaction) for reverse transcription reaction, wherein the specific reaction system is as follows: 15 min at 37 ℃, 5min at 55 ℃; 97 ℃, 5 min; 4 ℃ for 4 h. The PCR product was stored in a refrigerator at-20 ℃.
6. Fluorescent quantitative PCR reaction
The reaction system for detecting the relative expression of hsa _ circ _0047834 by fluorescent quantitative PCR (qRT-PCR) is as follows: mu.l SYBR, 0.4. mu.l ROX, 1. mu.l cDNA template, 0.5. mu.l forward primer at a concentration of 52.6. mu.g/mL, 0.5. mu.l reverse primer at a concentration of 48.2. mu.g/mL, ddH2O was added to 20. mu.l, and the reagent was added to the eight tubes, which were capped and then placed in a centrifuge for transient centrifugation. Then placing the mixture into a fluorescent quantitative PCR instrument for reaction, wherein the specific reaction system is as follows: 95 ℃ for 5 min; circulating for 35 times at 95 ℃ for 15s, 59 ℃ for 30s and 72 ℃ for 30 s; 95 ℃ for 1 min, 55 ℃ for 30s, 95 ℃ for 30 s. Wherein the specific nucleotide sequence is as follows: an upstream primer: 5'-GTTTTCACTGTTCGACCGGC-3', respectively; a downstream primer: 5'-GCTGCATCCCAATCGCAAAT-3' are provided.
7. Calculation of the relative expression of hsa _ circ _0047834 in pancreatic cancer samples
The invention selects an internal reference gene as a standard to carry out relative quantification, takes beta-actin as the internal reference gene, carries out normalization processing on the target hsa _ circ _0047834, and detects the relative expression quantity of the target hsa _ circ _0047834 in different samples through fluorescent quantitative PCR. The formula for fold change in expression is:
△Ct=Ct（hsa_circ_0047834）-Ct (β-actin)
△△Ct(Cancer)=△Ct（Cancer）-△Ct (normal)；
2-△△Ct=2-（△Ct（Cancer）-△Ct (normal)）
wherein 2-△△CtRelative expression amount, 2-△△CtThe higher the value of (a), the higher the expression level of hsa _ circ _0047834, the higher Ct (hsa _ circ _ 0047834) and Ct (β -actin) represent the Ct values of the target hsa _ circ _0047834 and the reference gene β -actin, respectively, which are detected by fluorescence quantification, Cancer represents a pancreatic Cancer tumor sample, and Normal represents a Normal control sample. And (3) setting a negative control group in the quantitative experiment, repeating three times of wells for each sample, replacing a cDNA template of the sample with DEPC water in the negative control, and judging whether pollution exists according to the amplification condition of the negative control wells. As shown in FIG. 1, the hsa _ circ _0047834 primer is shown to be capable of specifically amplifying a fragment of interest.
8. Analysis of results
The GraphPad Prism 8 software of the experiment counts and analyzes data, and analyzes data by using rank sum test. Expression of hsa _ circ _0047834 in pancreatic cancer samples was detected by qRT-PCR and was found to be significantly higher in pancreatic cancer tissues than in normal paired tissues (P values were all less than 0.01, see figure 2A). At the same time, the expression of hsa _ circ _0047834 in pancreatic cancer plasma was significantly higher than that in normal human plasma (P values were all less than 0.01, see fig. 2B). The inventors further evaluated their subject working characteristic curves (ROC curves) in order to identify whether hsa _ circ _0047834 could be a biomarker for pancreatic cancer. The area under the ROC curve (AUC) was 0.8027, with sensitivity and specificity of 0.71 and 0.95, respectively (fig. 3). It is suggested that detecting the relative expression of hsa _ circ _0047834 is of high value for the diagnosis of pancreatic cancer.
The kit provided by the invention utilizes a SYBR Green fluorescent quantitative PCR method to detect the relative expression of hsa _ circ _0047834 in tissues and plasma samples of pancreatic cancer patients, and has the following characteristics: (1) the operation steps are simple and convenient, and the period is short. The kit can detect 386 samples at most simultaneously, and greatly shortens the detection time. (2) The stability is high. The kit can be stored at-20 deg.C for 18 months, and has no change in specificity and sensitivity. The invention provides a detection method which is simple to operate, high in sensitivity, strong in specificity, short in period and stable in result by detecting the relative expression of hsa _ circ _0047834 in pancreatic cancer tissues and blood plasma and combining a statistical principle and a modern biological technology, and provides a scientific basis for diagnosis and treatment of patients.
The above description is not intended to limit the present invention, and the present invention is not limited to the above examples. Those skilled in the art should also realize that changes, modifications, additions and substitutions can be made without departing from the true spirit and scope of the invention.
Claims (1)
1. The application of a reagent for detecting the relative expression quantity of hsa _ circ _0047834 in the preparation of a pancreatic cancer diagnostic kit is characterized in that: the reagent comprises a pair of specific amplification primers of hsa _ circ _004783 gene, and the specific nucleotide sequence is as follows: an upstream primer: 5'-GTTTTCACTGTTCGACCGGC-3', respectively; a downstream primer: 5'-GCTGCATCCCAATCGCAAAT-3' is added.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010908496.8A CN112159845B (en) | 2020-09-02 | 2020-09-02 | Application of circular RNA as pancreatic cancer diagnosis marker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010908496.8A CN112159845B (en) | 2020-09-02 | 2020-09-02 | Application of circular RNA as pancreatic cancer diagnosis marker |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112159845A CN112159845A (en) | 2021-01-01 |
| CN112159845B true CN112159845B (en) | 2022-07-12 |
Family
ID=73858594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010908496.8A Active CN112159845B (en) | 2020-09-02 | 2020-09-02 | Application of circular RNA as pancreatic cancer diagnosis marker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112159845B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107760784A (en) * | 2017-11-08 | 2018-03-06 | 中山大学附属第医院 | Circular rna circ FOXP1 purposes |
| CN107828888A (en) * | 2017-11-09 | 2018-03-23 | 中山大学附属第医院 | Circular rna circ PTPRA purposes |
-
2020
- 2020-09-02 CN CN202010908496.8A patent/CN112159845B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107760784A (en) * | 2017-11-08 | 2018-03-06 | 中山大学附属第医院 | Circular rna circ FOXP1 purposes |
| CN107828888A (en) * | 2017-11-09 | 2018-03-23 | 中山大学附属第医院 | Circular rna circ PTPRA purposes |
Non-Patent Citations (4)
| Title |
|---|
| Circular RNA expression profiles in extracellular vesicles from the plasma of patients with pancreatic ductal adenocarcinoma;Qingqing Li等;《FEBS Open Bio.》;20191105;第9卷(第12期);第2052-2062页 * |
| hsa_circ_0047834;Julia Salzman等;《cricBase》;20130905;第1-5页 * |
| The PMAIP1 gene on chromosome 18 is a candidate tumor suppressor gene in human pancreatic cancer;Ishida M等;《Dig Dis Sci.》;20080131;第53卷(第9期);第2576-2582页 * |
| 环状RNA在胰腺癌中的研究进展;纪道林等;《实用肿瘤杂志》;20190810;第34卷(第4期);第302-308页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112159845A (en) | 2021-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108179190B (en) | Plasma exosome circRNA marker of non-small cell lung cancer and detection primer and kit thereof | |
| CN107043823B (en) | Tumor marker related to colorectal cancer and application | |
| Li et al. | Plasma exosomal miR-125a-5p and miR-141-5p as non-invasive biomarkers for prostate cancer. | |
| CN107012145A (en) | A kind of long non-coding RNA and its application in diagnosis/treatment cholangiocarcinoma | |
| CN108531586B (en) | Circulating miRNA marker on X chromosome related to breast cancer auxiliary diagnosis and application thereof | |
| CN108866187B (en) | Long-chain non-coding RNA marker related to lung cancer auxiliary diagnosis and application thereof | |
| CN107881238A (en) | The miRNA marker related to colorectal cancer prognosis and its application | |
| CN112980947A (en) | Primer and kit for detecting circulating microRNA (microribonucleic acid) related to lung cancer diagnosis and treatment | |
| CN107058574B (en) | Tumor marker related to nasopharyngeal carcinoma and application thereof | |
| CN112159845B (en) | Application of circular RNA as pancreatic cancer diagnosis marker | |
| CN106939354B (en) | Application of miRNA-4530 as lung cancer diagnosis marker | |
| CN112195239B (en) | Esophageal squamous carcinoma metastatic tissue and serum exosome marker and application thereof | |
| CN113151462B (en) | Application of lung cancer prognosis diagnosis marker and detection kit | |
| CA3067527A1 (en) | Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method | |
| CN106929599B (en) | Application of miRNA-6126 as lung cancer diagnosis marker | |
| CN111575374A (en) | Molecular marker for early pancreatic tumor detection, and detection method and application thereof | |
| CN116121245B (en) | Small molecule RNA and application thereof in early diagnosis of endometriosis | |
| CN110257514A (en) | A kind of new cancer of the esophagus blood miRNA marker and its application | |
| CN114836423B (en) | Application of circular RNA in preparation of breast cancer diagnosis product | |
| CN114292920B (en) | Group of gastric precancerous lesions and gastric early diagnosis plasma RNA marker combination and application | |
| CN113999852B (en) | Application of circ_0001772 as colorectal cancer diagnosis and treatment marker | |
| CN110628907B (en) | Gallbladder cancer plasma exosome microRNAs markers and application thereof | |
| CN112176060B (en) | Plasma non-coding RNA and primer set for detecting expression level thereof and colorectal cancer detection kit | |
| CN115948546B (en) | Exosome miRNA biomarker for breast cancer and application thereof | |
| CN116083570A (en) | Application of urinary sediment SNORD15A as early tumor marker |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Wang Jianhua Inventor after: Zhu Yuchao Inventor before: Zhu Yuchao |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230911 Address after: 315000 No. 59 Liuting Street, Haishu District, Ningbo City, Zhejiang Province Patentee after: The First Affiliated Hospital of Ningbo University Address before: Room 204, 73 Jima Road, maqiaoji Town, Wangdian Town, Xiuzhou District, Jiaxing City, Zhejiang Province 314000 Patentee before: Zhu Yuchao |